With Libtayo's second approval, Regeneron digs deeper into PD-1 dermato-oncology niche
With the sixth checkpoint inhibitor to enter the US market, Regeneron execs have insisted that they can carve out a respectable market share for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
